Hematologic aspects of mastocytosis: II: Management of hematologic disorders in association with systemic mast cell disease

53Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Individuals with systemic mast cell disease (SMCD) may develop various hematologic abnormalities, including cytopenias, myeloproliferative or myelodysplastic syndromes, lymphoproliferative syndromes, and primary or secondary leukemias. Management of those patients is often complicated by their associated hematologic abnormalities. In the case of non-malignant hematologic syndromes, the approach to management is supportive. At present, overt malignancies are managed with traditional chemotherapy. The presence of leukemia in patients with mast cell disease usually indicates a grave prognosis. © 1991.

Cite

CITATION STYLE

APA

Parker, R. I. (1991). Hematologic aspects of mastocytosis: II: Management of hematologic disorders in association with systemic mast cell disease. Journal of Investigative Dermatology, 96(3). https://doi.org/10.1111/1523-1747.ep12469045

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free